Axsome Therapeutics Inc.
Axsome Therapeutics Reports Strong 2023 Financial Performance and Provides Pipeline Updates
Summary
Axsome Therapeutics, Inc. reported a significant increase in net product revenues for Q4 and full-year 2023, with year-over-year growth of 193% and 309%, respectively. The company also expanded its sales force for Auvelity, achieved broad payer coverage for Sunosi, and made advancements in its development pipeline. Key highlights include the enrollment completion of the SYMPHONY Phase 3 trial in narcolepsy and the anticipation of topline results in Q1 2024. Axsome is also preparing NDA submissions for AXS-14 in fibromyalgia and AXS-07 in migraine, both expected in H1 2024.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement